About Von Willebrand Disease — What is VWD
Humat-P for VWD — High-Quality VWF
Using Humate-P
Dosage Calculator
Mix2Vial/Smaller Diluent
Reimbursement and Prescribing Information
The CSL Behring Commitment
Resources & Tools
News & Events
Important Safety Information
Prescribing Information
Dosing Calculator
VWF Densitometric Analysis
Request More Information
For Patients

Flexibility and Dosing

Humate-P® is labeled in VWF:RCo for dosing accuracy in von Willebrand disease (VWD)

  • Humate-P® vials are labeled (in IUs) in:
    — VWF:RCo activity for the treatment of VWD and
    — FVIII activity for the treatment of hemophilia A
  • Dosing corresponds with the VWF:RCo assay, the single most predictive assay for VWD2
    — Measures VWF activity3
    — Provides a quantitative measurement of VWF function by determining how well VWF helps platelets adhere to one another3
  • Dose is calculated based on an expected in vivo recovery of 2.0-IU/dL rise in VWF:RCo activity per every IU/kg of VWF:RCo administered
  • Ratio allows adjustment of VWF levels without raising FVIII to unacceptable levels1

Announcing packaging enhancements for Humate-P®

  1. Product package, vial, and diluent are clearly marked LOW, MID or HIGH
  2. Attractive box design highlights company name change and product
  3. Mix2Vial™ needle-free transfer device part of standard packaging

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also in indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P®.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

References

  1. Kraaijenhagen RA, in‘t Anker PS, Koopman MMW, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5-9.
  2. Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA, and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.Thromb Haemost. 2002;87:224-230.
  3. Haen PJ. Disorders of hemostasis. In: Harris-Young L, ed. Principles of Hematology. Dubuque, Iowa: Wm C Brown Publishers;1995:375-389.